TL;DR
Pulmonary hypertension (PH) disproportionately affects women, yet they often experience milder forms of the disease, a paradox linked to estrogen. This review explores how estrogen's metabolites, rather than the parent hormone, and the enzymes that process them, contribute to these sex-based differences and the "estrogen paradox" in PH. Understanding this complex interplay could unlock new therapeutic strategies.
What Problem Does This Paper Address?
Pulmonary hypertension (PH) is a serious condition characterized by high blood pressure in the lungs, leading to right heart failure and often death. Intriguingly, PH is more common in women, but paradoxically, they tend to have less severe disease than men. This "estrogen paradox" suggests that estrogen, a primary female sex hormone, plays a complex role. While exogenous estrogens can be protective, the precise mechanisms are unclear. This paper dives into the hypothesis that estrogen's metabolites and the enzymes that metabolize them are key to understanding these sex differences and the paradox in PH. The authors aim to untangle how these factors influence disease development and progression, potentially leading to better treatments.
Methods
This paper is a comprehensive review, not an experimental study. It synthesizes existing research from animal models and human studies. The authors analyze findings related to:
- Estrogen Metabolism Pathways: Detailing the enzymatic processes (Phase I hydroxylation by CYPs, Phase II methylation, sulfonation, and glucuronidation) that transform estradiol (E2) into various metabolites.
- Estrogen Metabolites in PH: Examining the specific roles of key metabolites like 16α-OHE (pro-inflammatory, pro-proliferative), 2-ME2 (vasoprotective, anti-proliferative), and 4-OHE2 (complex, potentially exacerbating or ameliorating) in PH pathogenesis.
- Estrogen-Metabolizing Enzymes in PH: Investigating how the expression and activity of enzymes like Cytochrome P450s (CYPs) and 17ẞ-hydroxysteroid dehydrogenases (HSD17Bs) are altered in PH and how these changes might contribute to sex differences.
- Therapeutic Interventions: Reviewing current and potential medical therapies targeting estrogen metabolism for PH.
Datasets
Not discussed in the paper. This is a review article synthesizing existing literature.
Key Insights and Ideas
- Metabolites, Not Just the Hormone: The "estrogen paradox" in PH is likely driven by the diverse effects of estrogen metabolites, not just estradiol itself. Some metabolites promote disease, while others protect against it.
- Sex-Specific Metabolism: There are significant sex differences in the levels of certain estrogen metabolites (e.g., higher 4-OHEs and 16α-OHEs in females) and in the expression/activity of metabolizing enzymes, which could explain why women are more susceptible to PH but may experience milder forms.
- Hypoxia's Disruptive Role: The hypoxic environment characteristic of PH can disrupt the delicate balance of estrogen metabolism by altering enzyme activity, further complicating the picture.
- 2-ME2: A Potential Hero: The metabolite 2-methoxyestradiol (2-ME2) consistently emerges as a protective factor, suppressing proliferation, promoting vasodilation, and mitigating inflammation and mitochondrial dysfunction in PH models.
- 16α-OHE: A Potential Villain: Conversely, 16α-hydroxyestrone (16α-OHE) appears to promote PH by inducing oxidative stress, cell proliferation, endothelial-to-mesenchymal transition (EndoMT), and inflammation.
- Enzyme Dysregulation is Key: Changes in the expression and activity of enzymes like CYPs and HSD17Bs in PH patients, potentially influenced by factors like inflammation and hypoxia, are crucial for understanding the altered metabolite profiles and their impact on the disease.
Key Results
The paper doesn't present new quantitative experimental results but synthesizes findings from numerous studies:
- Sex Disparities in Metabolites: Studies show higher levels of 4-OHEs and 16α-OHEs in female lung tissues compared to males, and even higher in female smokers. Conversely, protective 2-OMEs are also higher in females.
- Enzyme Expression Changes: CYP1B1 is highly expressed in pulmonary artery lesions of PH patients. Hypoxia can alter CYP activity. HSD17B1 expression is upregulated by inflammatory cytokines, while HSD17B2 is inhibited by factors like TGF-β1.
- Therapeutic Potential:
- Anastrozole (an aromatase inhibitor) reduced E2 levels and pulmonary vascular remodeling in PH models but had mixed results in human trials.
- Fulvestrant showed promise in improving right ventricular function by reducing 16α-OHE2.
- Exogenous 2-ME2 supplementation demonstrated therapeutic effects in hypoxia-induced PH models.
- Traditional Chinese medicines targeting HSD17B and CYPs also show beneficial effects.
Limitations and Future Work
- Controversy over 4-OHE2: The exact role of 4-OHE2 in PH remains debated, with some studies suggesting it exacerbates the condition and others indicating it may ameliorate it.
- Sex Differences in Enzymes: While sex differences in estrogen metabolite levels are noted, direct evidence for sex-based differences in the expression of key metabolizing enzymes (like CYPs) in PH patients is still lacking. Further research is needed to confirm the hypothesis that gender-specific regulation of HIF-1α might contribute to these differences.
- HSD17B1 Expression Uncertainty: The precise role and expression levels of HSD17B1 in PH are unclear, and direct evidence is needed.
- Postmenopausal Women: The decline in HSD17B levels after menopause could contribute to the higher incidence and severity of PH in this demographic, but direct evidence is needed.
- Future Directions: The authors emphasize the need for further research to investigate sex differences in estrogen-metabolizing enzymes and the underlying molecular mechanisms in PH. This understanding is crucial for developing targeted therapies. The precise utilization of estrogen metabolites, considering the duration of hypoxia, could lead to superior exogenous estrogen therapy outcomes.
Summary updated